Pancreatic Cancer Research

ResearcherWuhan Union HospitalActive in the last 2 years

Hongkun Cai

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0056-2364; OpenAlex author ID A5157945882. Sources: OpenAlex.

Their work

Papers
3
Trials
0
Grants
0
Labs led
0
Collaborators
12
Papers, trials and grants by year

2022: 1 paper · 2023: none · 2024: none · 2025: none · 2026: 2 papers

Papers 3

  1. PRMT1-Mediated Arginine Methylation Redirects SMAD4 Signaling to Promote Metastasis in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-26-0923↗
  2. E2F3 activates NF-κB signaling through TRIM26 mediated TAB1 ubiquitination in pancreatic cancer. Co-author DOI 10.7150/ijbs.127710↗
  3. Overexpressed integrin alpha 2 inhibits the activation of the transforming growth factor β pathway in pancreatic cancer via the TFCP2-SMAD2 axis. Co-author DOI 10.1186/s13046-022-02286-5↗

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Heshui Wu · 3 shared papers, 2022–2026 · strength 0.74
  2. Yingke Zhou · 2 shared papers, 2026 · strength 0.56
  3. Dianyun Ren · 2 shared papers, 2022–2026 · strength 0.49
  4. Feng Guo · 1 shared paper, 2026 · strength 0.30
  5. Qiyue Zhang · 1 shared paper, 2026 · strength 0.30
  6. Tao Yin · 1 shared paper, 2026 · strength 0.26
  7. Gengdu Qin · 1 shared paper, 2026 · strength 0.26
  8. Yizhou Liu · 1 shared paper, 2026 · strength 0.26
  9. Taoyu Chen · 1 shared paper, 2026 · strength 0.26
  10. Shanmiao Gou · 1 shared paper, 2026 · strength 0.26
  11. Feng Guo · 1 shared paper, 2022 · strength 0.19
  12. Xin Jin · 1 shared paper, 2022 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.